# US 2010/0168123 A1 · Akt protein kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168123 A1
- Document ID: US20100168123A1
- Status: Published application
- Kind: A1
- Application number: 12/567,258
- Filed: 2009-09-25
- Published: 2010-07-01
- Earliest claimed: 2003-11-21
- Assignees: Array BioPharma Inc.; Genentech, Inc.
- Inventors: Ian S. Mitchell; Keith L. Spencer; Peter Stengel; Yongxin Han; Nicholas C. Kallan; Mark Munson; Guy P.A. Vigers; James Blake; Anthony Piscopio; John Josey; Scott Miller; Dengming Xiao; Rui Xu; Chang Rao; Bing Wang; April L. Bernacki
- Web page: https://patentgrep.com/patent/US20100168123A1

## CPC

- C07D 239/94: Nitrogen atoms
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B41M 3/008: {Sequential or multiple printing, e.g. on previously printed background; Mirror printing; Recto-verso printing; using a combination of different printing techniques; Printing of patterns visible in reflection and by transparency; by superposing printed artifacts}
- B44F 1/10: Changing, amusing, or secret pictures
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 237/28: Cinnolines
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 239/47: One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C07D 239/48: Two nitrogen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 495/04: Ortho-condensed systems
- G09F 13/16: Signs formed of or incorporating reflecting elements or surfaces, e.g. warning signs having triangular or other geometrical shape
- Y10T 428/24802: Discontinuous or differential coating, impregnation or bond [e.g., artwork, printing, retouched photograph, etc.]
- Y10T 428/24851: Intermediate layer is discontinuous or differential
- Y10T 428/25: Web or sheet containing structurally defined element or component and including a second component containing structurally defined particles
- Y10T 428/31507: Of polycarbonate
- Y10T 428/31551: Of polyamidoester [polyurethane, polyisocyanate, polycarbamate, etc.]
- Y10T 428/31786: Of polyester [e.g., alkyd, etc.]
- Y10T 428/31855: Of addition polymer from unsaturated monomers
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B41M: PRINTING, DUPLICATING, MARKING, OR COPYING PROCESSES; COLOUR PRINTING, (correction of typographical errors B41J; processes for applying transfer pictures or the like B44C1/16; fluid media for correction of typographical errors by coating C09D10/00; printing textiles D06P)
- B44F: SPECIAL DESIGNS OR PICTURES
- G09F: DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

## Claims

### Claim 1

A compound including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, said compound comprising Formula I:
A-L-CR I
where:
CR is quinoline, wherein said quinoline is optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, —NR21S2R24, —SO2NR21R22, —NR21S(O)R4, —S(O)NR21R22, —C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)OR21, —NR21C(O)OR24, —NR21C(═NR21)NR22R23, —NR21C(O)R22, —C(O)NR21R22, —SR21, —S(O)R24, —SO2R24, —NR21R22, —N21C(O)NR22R23, —NR21C(NCN)NR22R23, —OR21, C1-C4 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 heteroalkenyl, C2-C6 alkynyl, C2-C6 heteroalkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein any of said alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl are further optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C2-C6 heteroalkenyl, C2-C6 heteroalkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, —SR21, —S(O)R24, —SO2R24, —C(O)R21, —C(O)NR21R22, —C(O)NR21R22 and —OR21;
L is selected from:
where R12 is hydrogen, halogen, hydroxy, cyano, nitro, amino, azido, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C1-C5 heteroalkyl, C2-C5 heteroalkenyl or C2-C5 heteroalkynyl, wherein any of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl are optionally substituted with one or more groups independently selected from halogen, cyano, nitro, amino, azido, C1-C4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy and trifluoromethoxy;
A is
W is N or CR15, provided that when L is a substituted or unsubstituted piperazinylene, W must be CR15;
G is hydrogen, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein any of said alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, amino, nitro, azido, —NR21SO2R24, —SO2NR21R22, —NR21S(O)R4, —S(O)NR21R22, —C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)OR21, —NR21C(O)0R24, —NR21C(═NR21)NR22R23, —NR21C(O)R22, —C(O)NR21R22, —SR21, —S(O)R24, —SO21R24, —NR21R22, —NR21C(O)NR22R23, —NR21C(NCN)NR22R23, —OR21, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, cycloalkyl, heterocycloalkyl aryl and heteroaryl;
B1 and B2 are independently absent or C1-C4 alkylene, C1-C4 heteroalkylene, C2-C4 alkenylene, C2-C4 heteroalkenylene, C2-C4 alkynylene, C2-C4 heteroalkynylene, C3-C6 cycloalkylene, and C3-C6 heterocycloalkylene, wherein any of said alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, cycloalkylene or heterocycloalkylene is optionally substituted with one or more groups independently selected from halogen, hydroxyl, cyano, nitro, azido, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, NR21R22 and OR21;
R21, R22 and R23 independently are hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C2-C6 heteroalkenyl, C2-C6 heteroalkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;
R24 is C1-C6 alkyl, C2-C6 alkenyl, C2-6 alkynyl, C1-C6 heteroalkyl, C2-6 heteroalkenyl, C2-6 heteroalkynyl, C3-6 cycloalkyl, C3-C6 heterocycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;
or any two of R21, R22, R23 or R24 together with the atom(s) to which they are attached form a 4 to 10 membered carbocyclic, aryl, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, aryl, heteroaryl or heterocyclic rings are optionally substituted with one or more groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R13 and R14 are independently hydrogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 heteroalkenyl, C2-C6 alkynyl, C2-C6 heteroalkynyl, C1-C6 cycloalkyl, C1-C6 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, —C(O)R21, C(O)OR21, C(═NR21)NR22R23 or —SO2R24,wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, arylalkyl or heteroarylalkyl is optionally substituted with one or more groups independently selected from halogen, hydroxyl, cyano, amino, nitro, azido, —NR21SO2R24, —SO2NR21R22, —NR21S(O)R4, —S(O)NR21R22, —C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)OR21, —NR21C(O)OR24, —NR21C(═NR21)NR22R23, —NR21C(O)R22, —C(O)NR21R22, —SR21, —S(O)R24, —SO2R24, —NR21R22, —NR21C(O)NR22R23, —NR21C(NCN)NR22R23, —OR21, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, cycloalkyl, heterocycloalkyl aryl and heteroaryl;
or R13 and R14 together with the atoms to which they are attached form a 4 to 10 membered carbocyclic, aryl, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, aryl, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halogen, cyano, nitro, azido, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, NR21R22 and OR21;
or R13 and an atom of B2 together with N form a 4 to 10 membered carbocyclic, aryl, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, aryl, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halogen, cyano, nitro, azido, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, NR21R22 and OR21;
R15 is hydrogen, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl or C2-C4 heteroalkynyl, wherein any of said alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl or heteroalkynyl is optionally substituted with one or more groups independently selected from halogen, hydroxyl, cyano, nitro, azido, NR21R22 and OR21;
or R13 and R15 together with atoms to which they are attached form a 3 to 10 membered carbocyclic, aryl, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, aryl, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halogen, cyano, nitro, azido, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, NR21R22 and OR21;
or, when W is CR15, R15 and an atom of B1 or B2 together with C, form a 3 to 10 membered carbocyclic, aryl, heteroaryl or heterocyclic ring, wherein any of said carbocyclic, aryl, heteroaryl and heterocyclic rings are optionally substituted with one or more groups independently selected from halogen, cyano, nitro, azido, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, NR21R22 and OR21.

### Claim 2 (depends on 1)

The compound of claim 1, where
CR is:
where X is CR1;
Y is CR2;
D1, D2, D3 and D4 are independently CR4;
is hydrogen, halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, amino, aminomethyl, dimethylamino, aminoethyl, diethylamino or ethoxy;
R2 is hydrogen, halogen, hydroxyl, cyano, nitro, amino, azido, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, C1-C6 cycloalkyl, Cl-C6 heterocycloalkyl, Cl-C6 aryl, or Cl-C6 heteroaryl, wherein any of said alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl are further optionally substituted with one or more groups independently selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, amino, aminomethyl, dimethylamino, aminoethyl, diethylamino and ethoxy;
is hydrogen, hydroxyl, cyano, amino, nitro, azido, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —NR21SO2R24, —SO2NR21R22, —NR21S(O)R4, —S(O)NR21R22, —C(O)R21, —C(O)OR21, —OC(O)OR21, —NR21C(O)OR24, —NR21C(═NR21)NR22R23, —NR21C(O)R22, —C(O)NR21R22, —SR21, —S(O)R24, —SO2R24, —NR21R22, —NR21C(O)NR22R23, —NR21C(NCN)NR22R23 or —OR21, wherein any of said alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, is optionally substituted with one or more groups independently selected from halogen, hydroxyl, cyano, amino, nitro, azido, —NR21SO2R24, —SO2NR21R22, —NR21S(O)R4, —S(O)NR21R22, —C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)OR21, —N21C(O)OR24, —NR21C(═NR21)NR22R23, —NR21C(O)R22, —C(O)NR21R22, —SR21, —S(O)R24, —SO2R24, —NR21R22, —NR21C(O)NR22R23, —NR21C(NCN)NR22R23, —OR21,C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, and wherein said alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl may optionally be further optionally substituted with one or more groups independently selected from halogen, hydroxyl, cyano, amino, nitro, azido, C1-C4 alkyl, C1-C4 heteroalkyl, C2-C4 alkenyl, C2-C4 heteroalkenyl, C2-C4 alkynyl, C2-C4 heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, —NR21R22, and —OR21.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 2)

The compound of claim 2, where L is selected from:

### Claim 7 (depends on 6)

The compound of claim 6, where L is:

### Claim 8 (depends on 2)

The compound of claim 2, where A is:

### Claim 9 (depends on 2)

The compound of claim 2, where A is:
where G is hydrogen, alkyl, cycloalkyl, heterocycloaryl, aryl or heteroaryl, wherein any of said alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, amino, nitro, azido, —NR21SO2R24, —SO2NR21R22, —NR21S(O)R4, —S(O)NR21R22, —C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)OR21, —NR21C(O)OR24, —NR21C(═NR21NR22R23, —NR21C(O)R22, —C(O)NR21R22, —S R21, —S(O)R24, —SO2R24, —NR21R22, —NR21C(O)NR22R23, —NR21C(NCN)NR22R23, —OR21, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, cycloalkyl, heterocycloalkyl aryl and heteroaryl.

### Claim 10 (depends on 6)

The compound of claim 6, where A is:
where G is hydrogen, alkyl, cycloalkyl, heterocycloaryl, aryl or heteroaryl, wherein any of said alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one or more groups selected from halogen, hydroxyl, cyano, amino, nitro, azido, —NR21SO2R24, —SO2NR21R22, —NR21S(O)R4, —S(O)NR21R22, —C(O)R21, —C(O)OR21, —OC(O)R21, —0C(O)R21, —OCC(O)OR21, —NR21C(O)OR24, —NR21C(═NR21)NR22R23, —NR21C(O)R22, —C(O)NR21R22, —SR21, —S(O)R24, —SO2R24, —NR21R22, —NR21C(O)NR22R23, —NR21C(NCN)NR22R23, —OR21, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, cycloalkyl, heterocycloalkyl aryl and heteroaryl.

### Claim 11 (depends on 6)

The compound of claim 6, wherein A comprises:
where B1 and B2 are, independently, absent or C1-C4 alkylene;
R21a—R21c are independently H, halogen, CH3, CF3, CH3O, CN, NO2, NH2, Ph, OH, or OCH2Ph;
R22a, R22b, and R24 are independently H, CH3, or halogen;
R23a is H; and
R23b is H, CH3, CH2NH2, CH2NHCH2, CH2CH2NH2, CH2CH2NHCH2, CH2CH2N(CH2)2, —(C═O)CH2NH2 or —(C═O)CH2CH2NH2;
or R23a and R23b are joined to complete a 5 or 6 membered heterocyclic ring.

### Claim 12 (depends on 7)

The compound of claim 7, wherein A comprises:
where B1 and B2 are, independently, absent or C1-C4 alkylene;
R21a—R21c are independently H, halogen, CH3, CF3, CH3O, CN, NO2, NH2, Ph, OH, or OCH2Ph;
R22a, R22b, and a are independently H, CH3, or halogen;
R23a is H; and
R23b is H, CH3, CH2NH2, CH2NHCH2, CH2CH2NH2, CH2CH2NHCH2, CH2CH2N(CH2)2, —(C═O)CH2NH2 or —(C═O)CH2CH2NH2;
or R23a and R23b are joined to complete a 5 or 6 membered heterocyclic ring.

### Claim 13 (depends on 6)

The compound of claim 6, wherein A comprises:
wherein R25 and R26 are independently H or CH3; and
R27 is 1-naphthyl, 2-naphthyl, 3′-benzylthienyl, 2′-thienyl, 2′-pyridyl, 3′-pyridyl, 4′-pyridyl, 4′-thiazolyl, or 3,3-diphenyl.

### Claim 14 (depends on 7)

The compound of claim 7, wherein A comprises:
wherein R25 and R26 are independently H or CH3; and
R27 is 1-naphthyl, 2-naphthyl, 3′-benzylthienyl, 2′-thienyl, 2′-pyridyl, 3′-pyridyl, 4′-pyridyl, 4′-thiazolyl, or 3,3-diphenyl.

### Claim 15 (depends on 6)

The compound of claim 6, where A is:

### Claim 16 (depends on 7)

The compound of claim 7, where A is:

### Claim 17 (depends on 7)

The compound of claim 7, where A is a D- or L-amino acid selected from the naturally occurring amino acids, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3- methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, cirtulline, homocysteine, homoserine, ornithine and methionine sulfone.

### Claim 18 (depends on 17)

The compound of claim 17, wherein the amino acid is alanine, phenylalanine, histidine, or tryptophan.

### Claim 19 (depends on 1)

The compound of claim 1, wherein the compound is:
including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof

### Claim at position 18

20-21. (canceled)

### Claim 22 (depends on 1)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 1 to said mammal.

### Claim 23 (depends on 2)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 2 to said mammal.

### Claim at position 21

24-26. (canceled)

### Claim 27 (depends on 6)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 6 to said mammal.

### Claim 28 (depends on 7)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 7 to said mammal.

### Claim 29 (depends on 8)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 8 to said mammal.

### Claim 30 (depends on 9)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 9 to said mammal.

### Claim 31 (depends on 10)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 10 to said mammal.

### Claim 32 (depends on 11)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 11 to said mammal.

### Claim 33 (depends on 12)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 12 to said mammal.

### Claim 34 (depends on 1)

A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 35 (depends on 2)

A composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

### Claim at position 31

36-38. (canceled)

### Claim 39 (depends on 7)

A composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.

### Claim 40 (depends on 9)

A composition comprising a compound of claim 9 and a pharmaceutically acceptable carrier.

### Claim at position 34

41-43. (canceled)

### Claim 44 (depends on 19)

A method of treating hyperproliferative diseases in a mammal comprising administering a therapeutically effective amount of the compound defined in claim 19 to said mammal.

### Claim 45 (depends on 22)

The method of claim 22, wherein the hyperproliferative disease is cancer or inflammation.

### Claim 46 (depends on 19)

A composition comprising a compound of claim 19 and a pharmaceutically acceptable carrier.
